Abstract
Objective To estimate the proportion of pre-symptomatic transmission of SARS-CoV-2 infection that can occur and timing of transmission relative to symptom onset.
Setting/design Secondary analysis of international published data.
Data sources Meta-analysis of COVID-19 incubation period and a rapid systematic review of serial interval and generation time, which are published separately.
Participants Studies were selected for analysis if they had transparent methods and data sources and they provided enough information to simulate full distributions of serial interval or generation time. Twenty-three estimates of serial interval and five of generation time from 17 publications were included.
Methods Simulations were generated of incubation period and of serial interval or generation time. From these, transmission times relative to symptom onset were calculated and the proportion of pre-symptomatic transmission was estimated.
Outcome measures Transmission time of SARS-CoV-2 relative to symptom onset and proportion of pre-symptomatic transmission.
Results Transmission time ranged from a mean of 2.91 (95% CI: 3.18-2.64) days before symptom onset to 1.20 (0.86-1.55) days after symptom onset. Unweighted pooling of estimates of transmission time based on serial interval resulted in a mean of 0.60 days before symptom onset (3.01 days before to 1.81 days after). Proportion of pre-symptomatic transmission ranged from 42.8% (39.8%-45.9%) to 80.6% (78.1%-83.0%). The proportion of pre-symptomatic transmission from pooled estimates was 56.4% (34.9%-78.0%).
Conclusions Whilst contact rates between symptomatic infectious and susceptible people are likely to influence the proportion of pre-symptomatic transmission, there is substantial potential for pre-symptomatic transmission of SARS-CoV-2 in a range of different contexts. Our work suggests that transmission is most likely in the day before symptom onset whereas estimates suggesting most pre-symptomatic transmission highlighted mean transmission times almost three days before symptom onset. This highlights the need for rapid case detection, contact tracing and quarantine.
Strengths and weaknesses of this study
We estimate the extent and variation of pre-symptomatic transmission of SARS-CoV-2 infection across a range of contexts. This provides important information for development and targeting of control policies and for the parameterisation of transmission models.
This is a secondary analysis using simulations based on published data, some of which is in pre-print form and not yet peer-reviewed. There is overlap in the contact tracing data that informed some of our source publications. We partially address this by summarising data at source location level as well as at study level.
Populations where symptomatic people are rapidly isolated are likely have relatively more pre-symptomatic transmission. This should be borne in mind whilst interpreting our results, but does not affect our finding that there is substantial potential for pre-symptomatic transmission of SARS-CoV-2 infection.
A strength of our approach is that it builds an understanding of pre-symptomatic transmission from a range of estimates in the literature, facilitates discussion for the drivers of variation between them, and highlights the consistent message that consideration of pre-symptomatic transmission is critical for COVID-19 control policy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All investigators are full-time employees (or retired former employees) of University College Dublin, the Irish Department of Agriculture, Food and the Marine (DAFM), or the Irish Health information and Quality Authority (HIQA). No additional funding was obtained for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is a secondary analysis of published data based on rapid systematic literature reviews. No work was conducted that required ethical approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in this manuscript are publicly available.
